Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2005-02-22
2005-02-22
Guzo, David (Department: 1636)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C424S093600, C435S069100, C435S455000, C435S456000, C435S320100
Reexamination Certificate
active
06858205
ABSTRACT:
A pseudotyped baculovirus comprises a deletion, inactivation or reduction from regulation of a baculovirus envelope protein gene, and is engineered to express an envelope protein from another virus or cell, or another protein or molecule that facilitates entry of the baculovirus into a non-host cell, or provided with a heterologous envelope protein or another protein or molecule that facilitates entry of the baculovirus into a non-host cell by other suitable means. Such baculoviruses can be used to efficiently deliver genes to mammalian cells or organisms, and such genes can be expressed either from the baculovirus genome, or integrated into the mammalian cell genome, and can be used for expression of proteins such that purification of secreted or other protein products does not require removal of contaminating baculovirus particles or baculovirus envelope proteins.
REFERENCES:
patent: 5750383 (1998-05-01), Blissard et al.
patent: WO 9811243 (1998-03-01), None
patent: WO 9909193 (1999-02-01), None
patent: WO 0005394 (2000-02-01), None
Verma et al., Nature, 1997, vol. 389, pp. 239-242.*
Mountain, TIBTECH, 2000, vol. 18, pp. 119-128.*
Anderson, Nature, 1998, vol. 392, pp. 25-30.*
Paillard, Human Gene Therapy, 1998, vol. 9, pp. 767-768.*
Juengst, BMJ, 2003, vol. 326, pp. 1410-1411.*
Loser et al., Current Gene Therapy, 2002, vol. 2, pp. 161-171.*
Ghosh et al., Molecular Therapy, 2002, vol. 6, No. 1, pp. 5-11.*
Kmiec, American Scientist, 1999, vol. 87, pp. 242-247.*
Arrienne et al., Gene Therapy 717: 1499-1503 (2000).
Boyce et al., “Baculovirus-mediated gene transfer into mammalian cells” Proc. Natl. Acad. Sci. USA 93, 2348-52 (1996).
Condreay et al., “Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector.” Proc. Natl. Acad. Sci. USA 96:127-132 (1999).
Delaney et al., “Use of the hepatitus B virus recombinant baculovirus-Hep G2 system to study the effects of beta 2′,3′ dideoxy 3′ thiaceydine on replication of hepatitus B virus and accumulation of covalently closed circular DNA” Antimicrob. Agents Chemother. 43, 2017-26 (1999).
Hofmann et al., “Baculovirus mediated gene therapy in the presence of human serum or blood facilitated by inhibition of the complement system” Gene Ther. 5,531-6 (1998).
Hofmann et al., “Efficient gene transfer into human hepatocytes by baculovirus vectors.” Proc. Natl. Acad. Sci. USA 92:10099-10103 (1995).
Li Ma et al., Baculovirus-Mediated Gene Transfer Into Pancreatic Islet Cells Diabetes 49(12): 1986-1992 (2000).
Sarkis er al., Proc. Natl. Acad. Sci. USA 97:14638-14643 (2000).
Murges et al., “Baculovirus transactivator IE1 is functional in mammalian cells.” J. Gen. Virol 78:1507-1510 (1997).
Palombo et al., “Site-specific integration on mammalian cells mediated by a new hybrid baculovirus-adeno-associated virus vector.” J. Virol. 72:5025-5034 (1998).
Prieto et al., “The promise of gene therapy in gastrointestinal and liver diseases.” Gut 52:ii49 (2003).
Primrose, et al., “Principles of Gene Manipulation, 6thEd.” Chapter 10, Blackwell Publishing (2002).
Sandig et al., “Gene transfer into hepatocytes and human liver tissue by baculovirus vectors.” Human Gene Ther. 20,1937-45 (1996).
Shoji et al., “Efficient gene transfer into various mammalian cells, including non-hepatic cells, by baculovirus vectors.” J. Gen. Virol. 78:2657-2664 (1997).
Song et al., “Combination treatment for osteosarcoma with baculoviral vector mediated gene therapy (p53) and Chemotherapy (adriamycin)” Experimental and Molecular Medicine, vol. 33(1): 46-53 (Mar. 2001).
Barsoum et al. “Efficient Tranduction of Mammalian Cells by a Recombinant Baculovirus Having the Vesicular Stomatitis Virus G Glycoprotein.” Human Gene Therapy, XX, XX, vol. 8, No. 17, Nov. 20, 1997, p. 2011-2018.
Boublik, Yven et al. “Eukaryotic Virus Display: Engineering the Major Surface Glycoprotein of the Autographa Californica Nuclear Polyhedrosis Virus (AcNPV) for the Presentation of Foreign Proteins on the Virus Surface.” Biotechnology. vol. 13. Oct. 1995. p. 1079-1084.
Mangor, J.T. et al. “A GP54-Null Baculovirus Pseudotyped with Vesicular Stomatitis Virus G Protein.” Journal of Virology, Mar. 2001. p. 2544-2556.
Blissard Gary W.
Mangor Jodie T.
Monsma Scott A.
Boyce Thompson Institute for Plant Research
Brown & Michaels PC
Guzo David
LandOfFree
GP64-null baculoviruses pseudotyped with heterologous... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with GP64-null baculoviruses pseudotyped with heterologous..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and GP64-null baculoviruses pseudotyped with heterologous... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3506118